Get the Stockscreener App
13.98
3.25%
-0.47
Greenwich LifeSciences Inc stock is currently priced at $13.98, with a 24-hour trading volume of 15,444.
It has seen a -3.25% decreased in the last 24 hours and a +7.13% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $14.55 pivot point. If it approaches the $13.92 support level, significant changes may occur.
Previous Close:
$14.45
Open:
$14.43
24h Volume:
15,444
Market Cap:
$180.04M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-19.97
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+1.67%
1M Performance:
+7.13%
6M Performance:
+30.53%
1Y Performance:
+19.08%
1D Range:
$13.78
$14.52
52W Range:
$7.58
$21.44
Greenwich LifeSciences Inc Stock (GLSI) Company Profile
Name
Greenwich LifeSciences Inc
Sector
Industry
Phone
832-819-3232
Address
Building 14, 3992 Bluebonnet Drive, Stafford
Greenwich LifeSciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich LifeSciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 2% - MarketBeat
MarketBeat
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 2% - Defense World
Defense World
Analysts Set Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Price Target at $18.14 - Defense World
Defense World
Do Institutions Own Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares? - Yahoo Movies UK
Yahoo Movies UK
HER2+ Breast Cancer Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine ... - Barchart
Barchart
How To Trade (GLSI) - Stock Traders Daily
Stock Traders Daily
Greenwich LifeSciences Inc Stock (GLSI) Financials Data
Greenwich LifeSciences Inc (GLSI) Net Income 2024
GLSI net income (TTM) was -$8.89 million for the quarter ending December 31, 2023, a -13.63% decrease year-over-year.
Greenwich LifeSciences Inc (GLSI) Cash Flow 2024
GLSI recorded a free cash flow (TTM) of -$6.48 million for the quarter ending December 31, 2023, a -4.49% decrease year-over-year.
Greenwich LifeSciences Inc (GLSI) Earnings per Share 2024
GLSI earnings per share (TTM) was -$0.70 for the quarter ending December 31, 2023, a -14.75% decline year-over-year.
Greenwich LifeSciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Mar 22 '24 |
Buy |
19.98 |
2,500 |
49,950 |
5,347,777 |
| Patel Snehal | CEO and CFO |
Mar 20 '24 |
Buy |
17.68 |
1,500 |
26,520 |
5,345,277 |
| Patel Snehal | CEO and CFO |
Mar 05 '24 |
Buy |
12.49 |
30,500 |
380,945 |
5,343,777 |
| Patel Snehal | CEO and CFO |
Mar 04 '24 |
Buy |
13.03 |
4,100 |
53,423 |
5,340,277 |
| Patel Snehal | CEO and CFO |
Feb 16 '24 |
Buy |
11.16 |
10,800 |
120,528 |
5,336,177 |
| Patel Snehal | CEO and CFO |
Feb 15 '24 |
Buy |
11.07 |
12,700 |
140,589 |
5,325,377 |
| Patel Snehal | CEO and CFO |
Nov 10 '23 |
Buy |
10.17 |
5,000 |
50,838 |
5,312,677 |
| Patel Snehal | CEO and CFO |
Nov 03 '23 |
Buy |
9.11 |
3,500 |
31,885 |
5,307,677 |
| Thompson Jaye | VP Clinical Reg Affairs |
Oct 27 '23 |
Buy |
8.57 |
500 |
4,285 |
260,348 |
| Patel Snehal | CEO and CFO |
Oct 26 '23 |
Buy |
7.97 |
2,500 |
19,925 |
5,304,177 |
About Greenwich LifeSciences Inc
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas.
0.77%
1.20%
Cap:
|
Volume (24h):